var data={"title":"Tinea versicolor (Pityriasis versicolor)","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Tinea versicolor (Pityriasis versicolor)</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/contributors\" class=\"contributor contributor_credentials\">Beth G Goldstein, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/contributors\" class=\"contributor contributor_credentials\">Adam O Goldstein, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/contributors\" class=\"contributor contributor_credentials\">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dd><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/contributors\" class=\"contributor contributor_credentials\">Moise L Levy, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/contributors\" class=\"contributor contributor_credentials\">Ted Rosen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/contributors\" class=\"contributor contributor_credentials\">Abena O Ofori, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jun 02, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tinea versicolor (ie, pityriasis versicolor) is a common superficial fungal infection. Patients with this disorder often present with hypopigmented, hyperpigmented, or erythematous macules on the trunk and proximal upper extremities (<a href=\"image.htm?imageKey=DERM%2F100026%7EDERM%2F100022%7EDERM%2F100020%7EDERM%2F100019%7EDERM%2F100021\" class=\"graphic graphic_picture graphicRef100026 graphicRef100022 graphicRef100020 graphicRef100019 graphicRef100021 \">picture 1A-E</a>). Unlike other disorders utilizing the term tinea (eg, tinea pedis, tinea capitis), tinea versicolor is not a dermatophyte infection. The causative organisms are saprophytic, lipid-dependent yeasts in the genus <em>Malassezia</em> (formerly known as <em>Pityrosporum</em>) [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Tinea versicolor responds well to medical therapy (<a href=\"image.htm?imageKey=DERM%2F100541\" class=\"graphic graphic_table graphicRef100541 \">table 1</a>), but recurrence is common and long-term prophylactic therapy may be necessary. The clinical features, diagnosis, and management of tinea versicolor will be reviewed here.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tinea versicolor occurs worldwide, but the highest incidence is found in tropical climates. Prevalence of up to 50 percent has been reported in some tropical countries [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/2\" class=\"abstract_t\">2</a>]. In Scandinavia, the prevalence has been estimated to be approximately 1 percent [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/2\" class=\"abstract_t\">2</a>].</p><p>Tinea versicolor most commonly affects adolescents and young adults, but can also occur in children and has been reported in infants [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/3-6\" class=\"abstract_t\">3-6</a>]. The disorder is not contagious, although successful inoculation has occurred under experimental conditions utilizing topical oils and occlusion [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/7,8\" class=\"abstract_t\">7,8</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">PATHOGENESIS AND RISK FACTORS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Malassezia</em> is a lipid-dependent, dimorphic fungus that is a component of normal skin flora. Transformation of <em>Malassezia</em> from yeast cells to a pathogenic mycelial form is associated with the development of clinical disease. External factors suspected of contributing to this conversion include exposure to hot and humid weather, hyperhidrosis, and the use of topical skin oils [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/9\" class=\"abstract_t\">9</a>]. Tinea versicolor is not related to poor hygiene.</p><p>Host characteristics that contribute to the development of tinea versicolor are poorly understood. A genetic predisposition may be involved [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/10\" class=\"abstract_t\">10</a>]. In a questionnaire-based study, 21 percent of patients reported a positive family history of the disease [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/11\" class=\"abstract_t\">11</a>]. Tinea versicolor also occurs more commonly in patients who are immunosuppressed, suggesting that an altered host immune response may play a role in the pathogenesis [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/12\" class=\"abstract_t\">12</a>]. Oral contraceptive therapy and malnutrition may be additional predisposing factors [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/13\" class=\"abstract_t\">13</a>].</p><p><em>M. globosa</em> appears to be the predominant causal species in tinea versicolor [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/14-16\" class=\"abstract_t\">14-16</a>]. <em>M. sympodialis</em>, <em>M. furfur</em>, and other <em>Malassezia</em> species have also been implicated [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/17\" class=\"abstract_t\">17</a>]. (See <a href=\"topic.htm?path=invasive-malassezia-infections\" class=\"medical medical_review\">&quot;Invasive Malassezia infections&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The term &quot;versicolor&quot; refers to the variable changes in cutaneous pigmentation that may occur in this disorder. The macules, patches, and thin plaques of tinea versicolor can be hypopigmented, hyperpigmented, or mildly erythematous (<a href=\"image.htm?imageKey=DERM%2F100026%7EDERM%2F100022%7EDERM%2F100020%7EDERM%2F100019%7EDERM%2F100021\" class=\"graphic graphic_picture graphicRef100026 graphicRef100022 graphicRef100020 graphicRef100019 graphicRef100021 \">picture 1A-E</a>). In light-skinned individuals, hyperpigmented tinea versicolor is often light brown. Hyperpigmented tinea versicolor may present as dark brown to gray-black macules and patches in those with dark skin (<a href=\"image.htm?imageKey=DERM%2F52438\" class=\"graphic graphic_picture graphicRef52438 \">picture 2</a>).</p><p>The color of affected areas can vary between individuals with similar skin color, and occasionally, between areas of involvement on one person. Although the reasons for pigmentary variation are unconfirmed, a few theories have been proposed. Patients with hypopigmented tinea versicolor often notice that the disorder is most prominent during the summer, when the affected areas fail to tan after sun exposure. Inhibitory or damaging effects on melanocytes by <a href=\"topic.htm?path=azelaic-acid-drug-information\" class=\"drug drug_general\">azelaic acid</a> (a dicarboxylic acid produced by <em>Malassezia</em>) may play a role in the development of hypopigmentation [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/18,19\" class=\"abstract_t\">18,19</a>]. Hyperpigmented and erythematous lesions may be a consequence of an inflammatory reaction to the yeast [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/18\" class=\"abstract_t\">18</a>].</p><p>A fine scale is often present on affected skin, which becomes more apparent when the lesion is scraped for microscopy. Individual lesions are typically small, but frequently coalesce into larger patches. In adolescents and adults, tinea versicolor is most commonly found on the upper trunk and proximal upper extremities, and less often on the face and intertriginous areas. In contrast, when tinea versicolor occurs in children, it is likely to involve the face (<a href=\"image.htm?imageKey=DERM%2F100025%7EDERM%2F100024\" class=\"graphic graphic_picture graphicRef100025 graphicRef100024 \">picture 3A-B</a>) [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/1,3\" class=\"abstract_t\">1,3</a>].</p><p>The distribution of tinea versicolor on the body may reflect the nutritional requirements of the yeast. <em>Malassezia</em> is lipid-dependent, and the greater sebum production by cutaneous sebaceous glands on the upper body may contribute to the predominance of tinea versicolor in this location. This theory may also account for the less frequent occurrence of this disorder in children and older adults, in whom sebum production is lower [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p>While most patients are asymptomatic, some complain of mild pruritus, and many are concerned about cosmesis. Although spontaneous remission has been reported [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/20\" class=\"abstract_t\">20</a>], the disorder can be persistent if untreated.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A diagnosis of tinea versicolor should be suspected when a patient presents with hypopigmented or hyperpigmented macules coalescing into patches on the upper trunk, proximal extremities, neck, or face. The variable clinical features of tinea versicolor and the existence of other skin disorders with similar findings make it preferable to confirm the diagnosis with a potassium hydroxide (KOH) preparation. Both hyphae and yeast cells are evident in a pattern that is often described as &quot;spaghetti and meatballs&quot; (<a href=\"image.htm?imageKey=PC%2F58965\" class=\"graphic graphic_picture graphicRef58965 \">picture 4</a>). Additionally, in approximately one-third of cases, examination with a Wood's lamp will reveal yellow to yellow-green fluorescence [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/17\" class=\"abstract_t\">17</a>]. (See <a href=\"topic.htm?path=office-based-dermatologic-diagnostic-procedures#H4044416\" class=\"medical medical_review\">&quot;Office-based dermatologic diagnostic procedures&quot;, section on 'Potassium hydroxide preparation'</a>.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of tinea versicolor consists of several common and uncommon skin disorders. The potassium hydroxide (KOH) preparation is a simple and reliable way to confirm the diagnosis. Examples of skin disorders that may resemble tinea versicolor include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Seborrheic dermatitis </strong>&ndash; Seborrheic dermatitis on the trunk is usually more erythematous than tinea versicolor, and typically has thicker scale. Patients often exhibit other areas of involvement such as the scalp, eyebrows, and nasolabial folds (<a href=\"image.htm?imageKey=DERM%2F56410\" class=\"graphic graphic_picture graphicRef56410 \">picture 5</a>). (See <a href=\"topic.htm?path=overview-of-dermatitis-eczema#H2\" class=\"medical medical_review\">&quot;Overview of dermatitis (eczema)&quot;, section on 'Seborrheic dermatitis'</a> and <a href=\"topic.htm?path=seborrheic-dermatitis-in-adolescents-and-adults#H34051773\" class=\"medical medical_review\">&quot;Seborrheic dermatitis in adolescents and adults&quot;, section on 'Clinical manifestations'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pityriasis rosea </strong>&ndash; Patients with classic pityriasis rosea present with inflammatory macules and small patches in a &quot;Christmas tree-like&quot; distribution on the trunk. A larger herald patch that precedes the widespread eruption is often noted. Lesions are erythematous and exhibit a collarette of scale (<a href=\"image.htm?imageKey=DERM%2F87126\" class=\"graphic graphic_picture graphicRef87126 \">picture 6</a>). In dark-skinned individuals, hyperpigmentation can be prominent (<a href=\"image.htm?imageKey=DERM%2F53701\" class=\"graphic graphic_picture graphicRef53701 \">picture 7</a>). (See <a href=\"topic.htm?path=pityriasis-rosea\" class=\"medical medical_review\">&quot;Pityriasis rosea&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Vitiligo </strong>&ndash; Vitiligo is characterized by completely depigmented macules and patches (<a href=\"image.htm?imageKey=PC%2F79198\" class=\"graphic graphic_picture graphicRef79198 \">picture 8</a>). In contrast, tinea versicolor exhibits hypopigmented skin lesions. (See <a href=\"topic.htm?path=vitiligo-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Vitiligo: Pathogenesis, clinical features, and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Erythrasma </strong>&ndash; Erythrasma may present with erythematous or hyperpigmented patches in the axillae or groin, and is included in the differential diagnosis of intertriginous tinea versicolor (<a href=\"image.htm?imageKey=DERM%2F59529%7EDERM%2F51713\" class=\"graphic graphic_picture graphicRef59529 graphicRef51713 \">picture 9A-B</a>). Sites of erythrasma exhibit coral-red fluorescence upon illumination with a Wood's lamp (<a href=\"image.htm?imageKey=DERM%2F62143\" class=\"graphic graphic_picture graphicRef62143 \">picture 10</a>). (See <a href=\"topic.htm?path=erythrasma\" class=\"medical medical_review\">&quot;Erythrasma&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pityriasis alba </strong>&ndash; Pityriasis alba is a mild form of eczematous dermatitis that presents with hypopigmented macules and small patches on the face, and less frequently on the upper extremities (<a href=\"image.htm?imageKey=DERM%2F60866%7EDERM%2F73576\" class=\"graphic graphic_picture graphicRef60866 graphicRef73576 \">picture 11A-B</a>). Fine scale may be visible. The disorder is most common in children with an atopic history. (See <a href=\"topic.htm?path=approach-to-the-patient-with-macular-skin-lesions#H13\" class=\"medical medical_review\">&quot;Approach to the patient with macular skin lesions&quot;, section on 'Pityriasis alba'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Secondary syphilis </strong>&ndash; Patients with secondary syphilis may present with erythematous to brown macules, papules, or small plaques in a generalized distribution (<a href=\"image.htm?imageKey=ID%2F68877\" class=\"graphic graphic_picture graphicRef68877 \">picture 12</a>). Skin involvement is often present on the palms and soles (<a href=\"image.htm?imageKey=ID%2F65500\" class=\"graphic graphic_picture graphicRef65500 \">picture 13</a>). (See <a href=\"topic.htm?path=syphilis-epidemiology-pathophysiology-and-clinical-manifestations-in-hiv-uninfected-patients#H8\" class=\"medical medical_review\">&quot;Syphilis: Epidemiology, pathophysiology, and clinical manifestations in HIV-uninfected patients&quot;, section on 'Clinical manifestations'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Confluent and reticulated papillomatosis of Gougerot and Carteaud </strong>&ndash;<strong> </strong>This uncommon cutaneous disorder usually occurs in young adults. Hyperpigmented, scaly patches with a reticulated appearance are present (<a href=\"image.htm?imageKey=DERM%2F67566%7EDERM%2F76296%7EDERM%2F54172%7EDERM%2F66671\" class=\"graphic graphic_picture graphicRef67566 graphicRef76296 graphicRef54172 graphicRef66671 \">picture 14A-D</a>). The neck, chest (particularly intermammary area), and upper back may be affected.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Mycosis fungoides </strong>&ndash; Mycosis fungoides may present as hypopigmented patches on the skin, with a predilection for the trunk and extremities (<a href=\"image.htm?imageKey=DERM%2F71926\" class=\"graphic graphic_picture graphicRef71926 \">picture 15</a>). This variant of the disorder occurs most commonly in individuals with dark skin. Fine scale, erythema, or infiltrated plaques may also be present. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-mycosis-fungoides\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Topical therapy is the treatment of choice for patients with tinea versicolor. Systemic therapy is typically reserved for patients with widespread or recurrent tinea versicolor, or for patients who have failed topical therapy (<a href=\"image.htm?imageKey=DERM%2F100541\" class=\"graphic graphic_table graphicRef100541 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/21\" class=\"abstract_t\">21</a>]. </p><p>High-quality comparative studies on the relative efficacy of specific treatments for tinea versicolor are limited, making the optimal approach to treatment unclear. A systematic review and meta-analysis of controlled trials found that most trials that compared treatment regimens or therapeutic agents were underpowered to detect meaningful differences [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/22\" class=\"abstract_t\">22</a>]. The results suggested that longer courses of treatment, higher concentrations of topical active ingredients, and higher doses of oral antifungals may improve cure rates; however additional studies are necessary to confirm this conclusion. A table listing common treatment regimens for tinea versicolor is provided (<a href=\"image.htm?imageKey=DERM%2F100541\" class=\"graphic graphic_table graphicRef100541 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H76227885\"><span class=\"h2\">Patient education</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prior to treatment, patients should be advised that changes in cutaneous pigment often persist after successful treatment. Restoration of normal pigmentation may take months after the completion of successful therapy. (See <a href=\"#H19\" class=\"local\">'Treatment failure'</a> below.)</p><p class=\"headingAnchor\" id=\"H76227692\"><span class=\"h2\">First-line therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Topical antifungal medications, topical <a href=\"topic.htm?path=selenium-sulfide-drug-information\" class=\"drug drug_general\">selenium sulfide</a>, and topical <a href=\"topic.htm?path=zinc-pyrithione-drug-information\" class=\"drug drug_general\">zinc pyrithione</a> are effective and well-tolerated first-line therapies for tinea versicolor (<a href=\"image.htm?imageKey=DERM%2F100541\" class=\"graphic graphic_table graphicRef100541 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/22\" class=\"abstract_t\">22</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h3\">Topical antifungals</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Topical azole antifungals, topical <a href=\"topic.htm?path=terbinafine-drug-information\" class=\"drug drug_general\">terbinafine</a>, and topical <a href=\"topic.htm?path=ciclopirox-drug-information\" class=\"drug drug_general\">ciclopirox</a> improve tinea versicolor via direct antifungal activity. Effective treatment regimens ranging from a few days to four weeks in length are reported in the literature [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/22\" class=\"abstract_t\">22</a>]. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Azole antifungals </strong>&ndash; Small randomized trials support the efficacy of various topical azole antifungals (<a href=\"image.htm?imageKey=PC%2F76148\" class=\"graphic graphic_table graphicRef76148 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/22\" class=\"abstract_t\">22</a>]. In one randomized trial, <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> 2% cream applied once daily for 11 to 22 days (mean 14 days) was superior to placebo (84 versus 22 percent achieved mycologic cure) [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/23\" class=\"abstract_t\">23</a>]. A typical course of treatment with a topical azole antifungal is daily application for two weeks. </p><p/><p class=\"bulletIndent1\">The shampoo formulation of <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> appears to be effective with a shorter duration of therapy. The shampoo is applied to affected areas and is washed off after five minutes. In a randomized trial, a single application of ketoconazole 2% shampoo was compared with treatment on three consecutive days. Both regimens resulted in mycologic cure in approximately 80 percent of patients [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/24\" class=\"abstract_t\">24</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=terbinafine-drug-information\" class=\"drug drug_general\">Terbinafine</a><strong> </strong>&ndash; Topical terbinafine 1% solution applied twice daily for one week has been proven effective in small randomized trials [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/25,26\" class=\"abstract_t\">25,26</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ciclopirox-drug-information\" class=\"drug drug_general\">Ciclopirox</a><strong> </strong>&ndash;<strong> </strong>Topical ciclopirox olamine 1% cream was effective in two small randomized trials when applied twice daily for 14 days [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/27\" class=\"abstract_t\">27</a>].</p><p/><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">Selenium sulfide</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Topical <a href=\"topic.htm?path=selenium-sulfide-drug-information\" class=\"drug drug_general\">selenium sulfide</a> exerts antifungal activity primarily through the promotion of shedding of the infected stratum corneum. In a randomized trial, application of selenium sulfide 2.5% lotion for 10 minutes for seven days was superior to placebo in achieving mycologic cure (81 versus 15 percent cured, respectively) [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/28\" class=\"abstract_t\">28</a>]. </p><p>The shampoo formulation of <a href=\"topic.htm?path=selenium-sulfide-drug-information\" class=\"drug drug_general\">selenium sulfide</a> 2.5% is often prescribed in clinical practice. Patients apply the shampoo to the affected area daily for one week. The shampoo is rinsed off after 10 minutes.</p><p>A non-prescription <a href=\"topic.htm?path=selenium-sulfide-drug-information\" class=\"drug drug_general\">selenium sulfide</a> 1% shampoo is also available, but the efficacy of this product for the treatment of tinea versicolor has not been studied. Selenium sulfide 2.25% foam is a newer product that is applied twice daily without rinsing.</p><p class=\"headingAnchor\" id=\"H21493682\"><span class=\"h3\">Zinc pyrithione</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In a controlled trial that included 40 patients with tinea versicolor, <a href=\"topic.htm?path=zinc-pyrithione-drug-information\" class=\"drug drug_general\">zinc pyrithione</a> 1% shampoo applied for five minutes per day for two weeks was more effective than placebo for the treatment of tinea versicolor [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/29\" class=\"abstract_t\">29</a>]. All patients treated with zinc pyrithione shampoo were successfully treated compared with none of the patients in the placebo group.</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Severe or recalcitrant disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Oral therapy is reserved for patients with tinea versicolor that is refractory to topical therapy or widespread disease that makes the application of topical drugs difficult [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/1,21\" class=\"abstract_t\">1,21</a>]. It is important to note that persistent dyspigmentation is not a good indicator of failure of topical therapy. (See <a href=\"#H19\" class=\"local\">'Treatment failure'</a> below.)</p><p class=\"headingAnchor\" id=\"H76228191\"><span class=\"h3\">Oral therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Oral azole antifungals such as <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> and <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> are effective for the treatment of tinea versicolor (<a href=\"image.htm?imageKey=DERM%2F100541\" class=\"graphic graphic_table graphicRef100541 \">table 1</a>). In contrast to topical <a href=\"topic.htm?path=terbinafine-drug-information\" class=\"drug drug_general\">terbinafine</a>, oral terbinafine is <strong>not</strong> effective [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/30\" class=\"abstract_t\">30</a>]. Similarly, <a href=\"topic.htm?path=griseofulvin-drug-information\" class=\"drug drug_general\">griseofulvin</a> cannot be used for this condition.</p><p>Systemic therapy is not used as a first-line treatment for limited tinea versicolor to minimize risk of adverse effects. Abnormalities in liver function tests and drug interactions can occur with systemic azole antifungals. (See <a href=\"topic.htm?path=pharmacology-of-azoles#H11\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Adverse effects'</a> and <a href=\"topic.htm?path=pharmacology-of-azoles#H31\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Drug interactions'</a>.)</p><p>Oral therapy is not typically used for the treatment of tinea versicolor in children.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h4\">Itraconazole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">Itraconazole</a> therapy for tinea versicolor in adults is usually given as 200 mg per day for five days. Multiple randomized trials have reported mycologic cure rates between 70 and 100 percent with 200 mg of itraconazole daily for seven days, and dose comparison studies have shown similar success with treatment durations of five days [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/31\" class=\"abstract_t\">31</a>]. </p><p>Data conflict on the efficacy of a single 400 mg dose of <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>. In a randomized, open-label trial, a single 400 mg dose was as effective as 200 mg daily for seven days [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/32\" class=\"abstract_t\">32</a>]. However, a low rate of response to a single 400 mg dose of itraconazole was reported in a trial that compared single-dose <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> and single-dose itraconazole [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/33\" class=\"abstract_t\">33</a>].</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h4\">Fluconazole</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">Fluconazole</a> for tinea versicolor in adults is typically given as a 300 mg dose once weekly for two weeks [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/31\" class=\"abstract_t\">31</a>]. In a small, uncontrolled study, 300 mg once weekly for two weeks led to mycologic and clinical cure in 75 percent of patients with tinea versicolor [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/34\" class=\"abstract_t\">34</a>]. A dose-finding randomized trial also supports the efficacy of this regimen; 300 mg once weekly for up to two weeks resulted in mycologic cure in 87 percent of patients [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/35\" class=\"abstract_t\">35</a>].</p><p>A single dose of <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> may be effective. In an uncontrolled study of 24 individuals with extensive or recurrent tinea versicolor treated with a single 400 mg dose of fluconazole, resolution of clinical disease occurred in 74 percent [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/36\" class=\"abstract_t\">36</a>].</p><p class=\"headingAnchor\" id=\"H76227917\"><span class=\"h2\">Other therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Additional topical and systemic therapies have been used for the treatment of tinea versicolor.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Topical agents </strong>&ndash; Whitfield ointment [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/37,38\" class=\"abstract_t\">37,38</a>] and <a href=\"topic.htm?path=sulfur-and-salicylic-acid-drug-information\" class=\"drug drug_general\">sulfur-salicylic acid</a> shampoo [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/39\" class=\"abstract_t\">39</a>] are effective for tinea versicolor, but may cause skin irritation in a minority of patients. Small uncontrolled studies suggest that propylene glycol [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/40\" class=\"abstract_t\">40</a>] and <a href=\"topic.htm?path=benzoyl-peroxide-drug-information\" class=\"drug drug_general\">benzoyl peroxide</a> [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/41\" class=\"abstract_t\">41</a>] may also improve tinea versicolor.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Oral </strong><a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> &ndash; Although oral ketoconazole was effective for tinea versicolor in small randomized trials [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/42,43\" class=\"abstract_t\">42,43</a>], <strong>life-threatening hepatotoxicity</strong> and adrenal insufficiency, along with multiple potential drug-drug interactions, have been reported with oral ketoconazole therapy, making it an unfavorable choice for the treatment of tinea versicolor. Although these adverse effects appear to be rare with the short duration of therapy used for tinea versicolor [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/44\" class=\"abstract_t\">44</a>], knowledge of the potential for hepatotoxicity and the wide availability of safer oral antifungal agents led the European Medicines Agency to release a 2013 recommendation that marketing authorizations for oral ketoconazole be suspended throughout the European Union [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/45\" class=\"abstract_t\">45</a>]. The US Food and Drug Administration (FDA) simultaneously removed its indication for use of the drug for dermatophyte and <em>Candida</em> infections based upon risks for hepatotoxicity, adrenal insufficiency, and drug-drug interactions. The FDA also recommended that oral ketoconazole should <strong>not</strong> be used as a first-line agent for any fungal infection. The indications for treatment of blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis have been retained only for patients in whom other antifungal treatments have failed or are not tolerated [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/46\" class=\"abstract_t\">46</a>]. (see <a href=\"topic.htm?path=pharmacology-of-azoles#H11\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Adverse effects'</a> and <a href=\"topic.htm?path=pharmacology-of-azoles#H25\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Ketoconazole'</a>)</p><p/><p class=\"bulletIndent1\">In 2016, following an FDA safety review that found continued prescribing of oral <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> for fungal skin and nail infections, the FDA released a drug safety communication warning healthcare professionals to <strong>avoid</strong> prescribing oral ketoconazole for fungal skin and nail infections [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/47\" class=\"abstract_t\">47</a>]. The risks of oral ketoconazole treatment outweigh the benefits. &#160;</p><p/><p class=\"headingAnchor\" id=\"H19\"><span class=\"h2\">Treatment failure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hypopigmentation and hyperpigmentation can persist for months following successful treatment of tinea versicolor, and may cause patients to assume incorrectly that treatment has failed. The presence of scale plus a positive potassium hydroxide (KOH) preparation is considered indicative of active infection.</p><p>Resistance to therapy, frequent recurrence, or widespread disease should prompt consideration of an immunodeficient state (<a href=\"image.htm?imageKey=ALLRG%2F71244\" class=\"graphic graphic_table graphicRef71244 \">table 3</a>).</p><p class=\"headingAnchor\" id=\"H76228585\"><span class=\"h2\">Emerging therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pramiconazole, a newer triazole antifungal, has been studied for the treatment of tinea versicolor. In a randomized trial, pramiconazole was superior to placebo at doses of 200 mg for two days, 200 mg for three days, and single doses of 200 mg or 400 mg (mycologic cure rates of 92, 96, 68, and 78 percent, respectively) [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/48\" class=\"abstract_t\">48</a>]. The drug is not yet available for clinical use.</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients who experience frequent recurrences of tinea versicolor (particularly immunosuppressed individuals) can prevent recurrences with use of topical or oral preventive therapy, particularly during warm weather. In our clinical experience, prophylaxis with topical <a href=\"topic.htm?path=selenium-sulfide-drug-information\" class=\"drug drug_general\">selenium sulfide</a> 2.5% or <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> 2% shampoo applied to the entire body for ten minutes once per month is an effective therapy.</p><p>Oral <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> is also used for prophylaxis. In a six-month randomized trial, a greater percentage of subjects were free of recurrent disease after prophylactic treatment with itraconazole (200 mg twice daily for one day per month) than with placebo (88 percent versus 57 percent, respectively) [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/49\" class=\"abstract_t\">49</a>]. <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">Ketoconazole</a> 400 mg one day per month was also reported to be effective for prophylaxis in a small, uncontrolled study [<a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/50\" class=\"abstract_t\">50</a>]. However, concerns regarding the safety of oral ketoconazole have led the European Medicines Agency and US Food and Drug Administration to recommend restrictions on the use of this agent. (See <a href=\"#H76227917\" class=\"local\">'Other therapies'</a> above and <a href=\"topic.htm?path=pharmacology-of-azoles#H25\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Ketoconazole'</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=tinea-versicolor-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Tinea versicolor (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H21\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tinea versicolor is a common fungal skin infection. The disorder occurs worldwide, but is most prevalent in tropical climates. Adolescents and young adults are affected most frequently. Tinea versicolor is not contagious. (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Malassezia</em> yeasts are a component of normal skin flora. The reasons for the development of tinea versicolor are likely to be multifactorial, involving both exogenous and endogenous factors. Immunosuppressed patients may be at increased risk for the disease. (See <a href=\"#H3\" class=\"local\">'Pathogenesis and risk factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with tinea versicolor can exhibit hypopigmented, hyperpigmented, or erythematous macules and patches (<a href=\"image.htm?imageKey=DERM%2F100026%7EDERM%2F100022%7EDERM%2F100020%7EDERM%2F100019%7EDERM%2F100021\" class=\"graphic graphic_picture graphicRef100026 graphicRef100022 graphicRef100020 graphicRef100019 graphicRef100021 \">picture 1A-E</a>). The most common areas of involvement include the upper trunk and proximal upper extremities; facial and intertriginous areas are less frequently affected (<a href=\"image.htm?imageKey=DERM%2F100025%7EDERM%2F100024\" class=\"graphic graphic_picture graphicRef100025 graphicRef100024 \">picture 3A-B</a>). (See <a href=\"#H4\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The potassium hydroxide (KOH) preparation is a quick and effective way to diagnose tinea versicolor. A Wood's lamp examination will reveal yellow to yellow-green fluorescence in a minority of patients. (See <a href=\"#H5\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Topical therapy is a safe and effective treatment for most patients with tinea versicolor. Topical azole antifungals, <a href=\"topic.htm?path=selenium-sulfide-drug-information\" class=\"drug drug_general\">selenium sulfide</a>, and <a href=\"topic.htm?path=zinc-pyrithione-drug-information\" class=\"drug drug_general\">zinc pyrithione</a> are effective and well-tolerated topical treatments (<a href=\"image.htm?imageKey=DERM%2F100541\" class=\"graphic graphic_table graphicRef100541 \">table 1</a>). Patients should be advised that pigmentary changes may take months to resolve. (See <a href=\"#H76227692\" class=\"local\">'First-line therapy'</a> above and <a href=\"#H19\" class=\"local\">'Treatment failure'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For adult patients with extensive disease, we suggest treatment with an oral azole antifungal rather than topical therapy (<a href=\"image.htm?imageKey=DERM%2F100541\" class=\"graphic graphic_table graphicRef100541 \">table 1</a>) (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H13\" class=\"local\">'Severe or recalcitrant disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with tinea versicolor who fail topical therapy can be treated with a systemic agent. Treatment regimens are the same as for patients with extensive disease. (See <a href=\"#H13\" class=\"local\">'Severe or recalcitrant disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recurrent disease is common. For patients who desire treatment and experience multiple recurrences per year, we suggest prophylactic therapy (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). We typically use once-monthly application of <a href=\"topic.htm?path=selenium-sulfide-drug-information\" class=\"drug drug_general\">selenium sulfide</a> or <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a> shampoo. If this regimen is not effective, we prescribe 400 mg of <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> (in two divided doses) once monthly for adults during the warm months of the year, when recurrence is most likely. (See <a href=\"#H20\" class=\"local\">'Prevention'</a> above.)</p><p/><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/1\" class=\"nounderline abstract_t\">Gupta AK, Batra R, Bluhm R, Faergemann J. Pityriasis versicolor. Dermatol Clin 2003; 21:413.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/2\" class=\"nounderline abstract_t\">Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol 2002; 16:19.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/3\" class=\"nounderline abstract_t\">Bouassida S, Boudaya S, Ghorbel R, et al. [Pityriasis versicolor in children: a retrospective study of 164 cases]. Ann Dermatol Venereol 1998; 125:581.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/4\" class=\"nounderline abstract_t\">Nanda A, Kaur S, Bhakoo ON, et al. Pityriasis (tinea) versicolor in infancy. Pediatr Dermatol 1988; 5:260.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/5\" class=\"nounderline abstract_t\">Jena DK, Sengupta S, Dwari BC, Ram MK. Pityriasis versicolor in the pediatric age group. Indian J Dermatol Venereol Leprol 2005; 71:259.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/6\" class=\"nounderline abstract_t\">Wyre HW Jr, Johnson WT. Neonatal pityriasis versicolor. Arch Dermatol 1981; 117:752.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/7\" class=\"nounderline abstract_t\">Faergemann J, Fredriksson T. Experimental infections in rabbits and humans with Pityrosporum orbiculare and P. ovale. J Invest Dermatol 1981; 77:314.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/8\" class=\"nounderline abstract_t\">BURKE RC. Tinea versicolor: susceptibility factors and experimental infection in human beings. J Invest Dermatol 1961; 36:389.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/9\" class=\"nounderline abstract_t\">Faergemann J. Pityriasis versicolor. Semin Dermatol 1993; 12:276.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/10\" class=\"nounderline abstract_t\">Hafez M, el-Shamy S. Genetic susceptibility in pityriasis versicolor. Dermatologica 1985; 171:86.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/11\" class=\"nounderline abstract_t\">He SM, Du WD, Yang S, et al. The genetic epidemiology of tinea versicolor in China. Mycoses 2008; 51:55.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/12\" class=\"nounderline abstract_t\">G&uuml;le&ccedil; AT, Demirbilek M, Se&ccedil;kin D, et al. Superficial fungal infections in 102 renal transplant recipients: a case-control study. J Am Acad Dermatol 2003; 49:187.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/13\" class=\"nounderline abstract_t\">Borelli D, Jacobs PH, Nall L. Tinea versicolor: epidemiologic, clinical, and therapeutic aspects. J Am Acad Dermatol 1991; 25:300.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/14\" class=\"nounderline abstract_t\">Morishita N, Sei Y. Microreview of Pityriasis versicolor and Malassezia species. Mycopathologia 2006; 162:373.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/15\" class=\"nounderline abstract_t\">Prohic A, Ozegovic L. Malassezia species isolated from lesional and non-lesional skin in patients with pityriasis versicolor. Mycoses 2007; 50:58.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/16\" class=\"nounderline abstract_t\">Karaka&#351; M, Tura&ccedil;-Bi&ccedil;er A, Ilkit M, et al. Epidemiology of pityriasis versicolor in Adana, Turkey. J Dermatol 2009; 36:377.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/17\" class=\"nounderline abstract_t\">Schwartz RA. Superficial fungal infections. Lancet 2004; 364:1173.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/18\" class=\"nounderline abstract_t\">Galadari I, el Komy M, Mousa A, et al. Tinea versicolor: histologic and ultrastructural investigation of pigmentary changes. Int J Dermatol 1992; 31:253.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/19\" class=\"nounderline abstract_t\">Nazzaro-Porro M, Passi S. Identification of tyrosinase inhibitors in cultures of Pityrosporum. J Invest Dermatol 1978; 71:205.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/20\" class=\"nounderline abstract_t\">Robertson LI. Itraconazole in the treatment of widespread tinea versicolor. Clin Exp Dermatol 1987; 12:178.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/21\" class=\"nounderline abstract_t\">Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: Pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol 1996; 34:287.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/22\" class=\"nounderline abstract_t\">Hu SW, Bigby M. Pityriasis versicolor: a systematic review of interventions. Arch Dermatol 2010; 146:1132.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/23\" class=\"nounderline abstract_t\">Savin RC, Horwitz SN. Double-blind comparison of 2% ketoconazole cream and placebo in the treatment of tinea versicolor. J Am Acad Dermatol 1986; 15:500.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/24\" class=\"nounderline abstract_t\">Lange DS, Richards HM, Guarnieri J, et al. Ketoconazole 2% shampoo in the treatment of tinea versicolor: a multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 1998; 39:944.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/25\" class=\"nounderline abstract_t\">Savin R, Eisen D, Fradin MS, Lebwohl M. Tinea versicolor treated with terbinafine 1% solution. Int J Dermatol 1999; 38:863.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/26\" class=\"nounderline abstract_t\">Vermeer BJ, Staats CC. The efficacy of a topical application of terbinafine 1% solution in subjects with pityriasis versicolor: a placebo-controlled study. Dermatology 1997; 194 Suppl 1:22.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/27\" class=\"nounderline abstract_t\">Treatment of tinea versicolor with a new antifungal agent, ciclopirox olamine cream 1%. Clin Ther 1985; 7:574.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/28\" class=\"nounderline abstract_t\">S&aacute;nchez JL, Torres VM. Double-blind efficacy study of selenium sulfide in tinea versicolor. J Am Acad Dermatol 1984; 11:235.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/29\" class=\"nounderline abstract_t\">Fredriksson T, Faergemann J. Double-blind comparison of a zinc pyrithione shampoo and its shampoo base in the treatment of tinea versicolor. Cutis 1983; 31:436.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/30\" class=\"nounderline abstract_t\">Leeming JP, Sansom JE, Burton JL. Susceptibility of Malassezia furfur subgroups to terbinafine. Br J Dermatol 1997; 137:764.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/31\" class=\"nounderline abstract_t\">Gupta AK, Lane D, Paquet M. Systematic review of systemic treatments for tinea versicolor and evidence-based dosing regimen recommendations. J Cutan Med Surg 2014; 18:79.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/32\" class=\"nounderline abstract_t\">K&ouml;se O, B&uuml;lent Ta&#351;tan H, Riza G&uuml;r A, Kurumlu Z. Comparison of a single 400 mg dose versus a 7-day 200 mg daily dose of itraconazole in the treatment of tinea versicolor. J Dermatolog Treat 2002; 13:77.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/33\" class=\"nounderline abstract_t\">Partap R, Kaur I, Chakrabarti A, Kumar B. Single-dose fluconazole versus itraconazole in pityriasis versicolor. Dermatology 2004; 208:55.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/34\" class=\"nounderline abstract_t\">Karaka&#351; M, Durdu M, Memi&#351;o&#287;lu HR. Oral fluconazole in the treatment of tinea versicolor. J Dermatol 2005; 32:19.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/35\" class=\"nounderline abstract_t\">Amer MA. Fluconazole in the treatment of tinea versicolor. Egyptian Fluconazole Study Group. Int J Dermatol 1997; 36:940.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/36\" class=\"nounderline abstract_t\">Faergemann J. Treatment of pityriasis versicolor with a single dose of fluconazole. Acta Derm Venereol 1992; 72:74.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/37\" class=\"nounderline abstract_t\">Clayton YM, Connor BL. Comparison of clotrimazole cream, Whitfield's ointment and Nystatin ointment for the topical treatment of ringworm infections, pityriasis versicolor, erythrasma and candidiasis. Br J Dermatol 1973; 89:297.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/38\" class=\"nounderline abstract_t\">Clayton R, Du Vivier A, Savage M. Double-blind trial of 1% clotrimazole cream and Whitfield ointment in the treatment of pityriasis versicolor. Arch Dermatol 1977; 113:849.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/39\" class=\"nounderline abstract_t\">Bamford JT. Treatment of tinea versicolor with sulfur-salicylic shampoo. J Am Acad Dermatol 1983; 8:211.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/40\" class=\"nounderline abstract_t\">Faergemann J, Fredriksson T. Propylene glycol in the treatment of tinea versicolor. Acta Derm Venereol 1980; 60:92.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/41\" class=\"nounderline abstract_t\">Prestia AE. Topical benzoyl peroxide for the treatment of tinea versicolor. J Am Acad Dermatol 1983; 9:277.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/42\" class=\"nounderline abstract_t\">Hay RJ, Midgeley G. Short course ketoconazole therapy in pityriasis versicolor. Clin Exp Dermatol 1984; 9:571.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/43\" class=\"nounderline abstract_t\">Zaias N. Pityriasis versicolor with ketoconazole. J Am Acad Dermatol 1989; 20:703.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/44\" class=\"nounderline abstract_t\">Goodless DR, Ramos-Caro FA, Flowers FP. Ketoconazole in the treatment of pityriasis versicolor: international review of clinical trials. DICP 1991; 25:395.</a></li><li class=\"breakAll\">www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001855.jsp&amp;mid=WC0b01ac058004d5c1 (Accessed on July 26, 2013).</li><li class=\"breakAll\">www.fda.gov/Drugs/DrugSafety/ucm362415.htm (Accessed on July 26, 2013).</li><li class=\"breakAll\">www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm502073.htm (Accessed on May 23, 2016).</li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/48\" class=\"nounderline abstract_t\">Faergemann J, Todd G, Pather S, et al. A double-blind, randomized, placebo-controlled, dose-finding study of oral pramiconazole in the treatment of pityriasis versicolor. J Am Acad Dermatol 2009; 61:971.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/49\" class=\"nounderline abstract_t\">Faergemann J, Gupta AK, Al Mofadi A, et al. Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor. Arch Dermatol 2002; 138:69.</a></li><li><a href=\"https://www.uptodate.com/contents/tinea-versicolor-pityriasis-versicolor/abstract/50\" class=\"nounderline abstract_t\">Rausch LJ, Jacobs PH. Tinea versicolor: treatment and prophylaxis with monthly administration of ketoconazole. Cutis 1984; 34:470.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4039 Version 17.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H21\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">PATHOGENESIS AND RISK FACTORS</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">CLINICAL FEATURES</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">DIAGNOSIS</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">TREATMENT</a><ul><li><a href=\"#H76227885\" id=\"outline-link-H76227885\">Patient education</a></li><li><a href=\"#H76227692\" id=\"outline-link-H76227692\">First-line therapy</a><ul><li><a href=\"#H10\" id=\"outline-link-H10\">- Topical antifungals</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">- Selenium sulfide</a></li><li><a href=\"#H21493682\" id=\"outline-link-H21493682\">- Zinc pyrithione</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">Severe or recalcitrant disease</a><ul><li><a href=\"#H76228191\" id=\"outline-link-H76228191\">- Oral therapies</a><ul><li><a href=\"#H15\" id=\"outline-link-H15\">Itraconazole</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Fluconazole</a></li></ul></li></ul></li><li><a href=\"#H76227917\" id=\"outline-link-H76227917\">Other therapies</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">Treatment failure</a></li><li><a href=\"#H76228585\" id=\"outline-link-H76228585\">Emerging therapy</a></li></ul></li><li><a href=\"#H20\" id=\"outline-link-H20\">PREVENTION</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H131844268\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/4039|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/100026\" class=\"graphic graphic_picture\">- Tinea versicolor on the upper trunk</a></li><li><a href=\"image.htm?imageKey=DERM/100022\" class=\"graphic graphic_picture\">- Tinea versicolor hyperpigmented</a></li><li><a href=\"image.htm?imageKey=DERM/100020\" class=\"graphic graphic_picture\">- Tinea versicolor erythematous</a></li><li><a href=\"image.htm?imageKey=DERM/100019\" class=\"graphic graphic_picture\">- Tinea versicolor on neck</a></li><li><a href=\"image.htm?imageKey=DERM/100021\" class=\"graphic graphic_picture\">- Tinea versicolor hypopigmented</a></li><li><a href=\"image.htm?imageKey=DERM/52438\" class=\"graphic graphic_picture\">- Tinea versicolor chest 2</a></li><li><a href=\"image.htm?imageKey=DERM/100025\" class=\"graphic graphic_picture\">- Tinea versicolor on the face</a></li><li><a href=\"image.htm?imageKey=DERM/100024\" class=\"graphic graphic_picture\">- Tinea versicolor on face and neck</a></li><li><a href=\"image.htm?imageKey=PC/58965\" class=\"graphic graphic_picture\">- Tinea versicolor potassium hydroxide</a></li><li><a href=\"image.htm?imageKey=DERM/56410\" class=\"graphic graphic_picture\">- Seborrheic dermatitis face</a></li><li><a href=\"image.htm?imageKey=DERM/87126\" class=\"graphic graphic_picture\">- Pityriasis rosea with herald patch</a></li><li><a href=\"image.htm?imageKey=DERM/53701\" class=\"graphic graphic_picture\">- Pityriasis rosea dark skin</a></li><li><a href=\"image.htm?imageKey=PC/79198\" class=\"graphic graphic_picture\">- Vitiligo generalized</a></li><li><a href=\"image.htm?imageKey=DERM/59529\" class=\"graphic graphic_picture\">- Erythrasma in axilla 2</a></li><li><a href=\"image.htm?imageKey=DERM/51713\" class=\"graphic graphic_picture\">- Intertriginous erythrasma</a></li><li><a href=\"image.htm?imageKey=DERM/62143\" class=\"graphic graphic_picture\">- Erythrasma fluorescence</a></li><li><a href=\"image.htm?imageKey=DERM/60866\" class=\"graphic graphic_picture\">- Pityriasis alba 1</a></li><li><a href=\"image.htm?imageKey=DERM/73576\" class=\"graphic graphic_picture\">- Pityriasis alba 2</a></li><li><a href=\"image.htm?imageKey=ID/68877\" class=\"graphic graphic_picture\">- Rash in secondary syphilis</a></li><li><a href=\"image.htm?imageKey=ID/65500\" class=\"graphic graphic_picture\">- Palmar rash secondary syphilis</a></li><li><a href=\"image.htm?imageKey=DERM/67566\" class=\"graphic graphic_picture\">- Confluent and reticulated papillomatosis - back</a></li><li><a href=\"image.htm?imageKey=DERM/76296\" class=\"graphic graphic_picture\">- Confluent and reticulated papillomatosis - chest</a></li><li><a href=\"image.htm?imageKey=DERM/54172\" class=\"graphic graphic_picture\">- Confluent and reticulated papillomatosis - close view</a></li><li><a href=\"image.htm?imageKey=DERM/66671\" class=\"graphic graphic_picture\">- Confluent and reticulated papillomatosis</a></li><li><a href=\"image.htm?imageKey=DERM/71926\" class=\"graphic graphic_picture\">- Hypopigmented mycosis fungoides</a></li></ul></li><li><div id=\"DERM/4039|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/100541\" class=\"graphic graphic_table\">- Therapeutic regimens - tinea versicolor</a></li><li><a href=\"image.htm?imageKey=PC/76148\" class=\"graphic graphic_table\">- Topical antifungal agents</a></li><li><a href=\"image.htm?imageKey=ALLRG/71244\" class=\"graphic graphic_table\">- Conditions associated with secondary immunodeficiency</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-macular-skin-lesions\" class=\"medical medical_review\">Approach to the patient with macular skin lesions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-mycosis-fungoides\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=erythrasma\" class=\"medical medical_review\">Erythrasma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=invasive-malassezia-infections\" class=\"medical medical_review\">Invasive Malassezia infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=office-based-dermatologic-diagnostic-procedures\" class=\"medical medical_review\">Office-based dermatologic diagnostic procedures</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-dermatitis-eczema\" class=\"medical medical_review\">Overview of dermatitis (eczema)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tinea-versicolor-the-basics\" class=\"medical medical_basics\">Patient education: Tinea versicolor (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-azoles\" class=\"medical medical_review\">Pharmacology of azoles</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pityriasis-rosea\" class=\"medical medical_review\">Pityriasis rosea</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=seborrheic-dermatitis-in-adolescents-and-adults\" class=\"medical medical_review\">Seborrheic dermatitis in adolescents and adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=syphilis-epidemiology-pathophysiology-and-clinical-manifestations-in-hiv-uninfected-patients\" class=\"medical medical_review\">Syphilis: Epidemiology, pathophysiology, and clinical manifestations in HIV-uninfected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vitiligo-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">Vitiligo: Pathogenesis, clinical features, and diagnosis</a></li></ul></div></div>","javascript":null}